EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC

• Autor principal: Fabio Villa (Autor)
• Formato: Libro
• Publicado: Journal of Surgery and Surgical Research - Peertechz Publications, 2015-12-17.
• Materias: Perspective Study
• Acceso en línea: Connect to this object online.

<p>5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Ki...